Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
| eano_guidelines [2025/05/12 06:55] – administrador | eano_guidelines [2025/05/12 06:56] (current) – administrador | ||
|---|---|---|---|
| Line 20: | Line 20: | ||
| Provides consensus recommendations for the treatment of PCNSL, including considerations for intraocular manifestations and specific management strategies for elderly and immunosuppressed patients. ([eano.eu][3]) | Provides consensus recommendations for the treatment of PCNSL, including considerations for intraocular manifestations and specific management strategies for elderly and immunosuppressed patients. ([eano.eu][3]) | ||
| - | **Brain Metastases from Solid Tumors | + | **Brain Metastases from Solid Tumors |
| Jointly developed with the [[European Society for Medical Oncology]] (ESMO), this guideline addresses the diagnosis, treatment, and follow-up of patients with [[brain metastases]] originating from solid tumors. | Jointly developed with the [[European Society for Medical Oncology]] (ESMO), this guideline addresses the diagnosis, treatment, and follow-up of patients with [[brain metastases]] originating from solid tumors. | ||